APPA-02 is under clinical development by Armata Pharmaceuticals and currently in Phase II for Bronchiectasis. According to GlobalData, Phase II drugs for Bronchiectasis have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how APPA-02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APPA-02 is under development for the treatment of multidrug-resistant chronic pulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients and non-CF bronchiectasis (NCFB). The drug candidate is a bacteriophage developed based on proprietary synthetic phage platform. It is administered through inhalational route.
Armata Pharmaceuticals overview
Armata Pharmaceuticals, formerly AmpliPhi Biosciences Corp, is a biotechnology company. It develops pathogen-specific bacteriophage drugs for the treatment of antibody-resistant bacterial infections. The company is investigating AP-PA02 drug against cystic fibrosis and non-CF bronchiectasis; and AP-PA03 to treat pneumonia. The company is also evaluating AP-SA02 program for the treatment of staphylococcus aureus infections such as bacteremia and periprosthetic joint infections (PJI). Armata Pharmaceuticals utilizes its proprietary synthetic phage platform to develop therapies for multidrug-resistant bacterial infections. It works in partnership with Merck & Co Inc to develop its products. Armata Pharmaceuticals is headquartered in Marina del Rey, California, the US.
For a complete picture of APPA-02’s drug-specific PTSR and LoA scores, buy the report here.